Searched for: in-biosketch:true
person:raos12
Association of plasma pentraxin 3 concentration with angiographic and clinical outcomes in patients with acute ST-segment elevation myocardial infarction treated by primary angioplasty
Dharma, Surya; Sari, Novi Y; Santoso, Anwar; Sukmawan, Renan; Rao, Sunil V
OBJECTIVE:To evaluate the association of plasma long pentraxin 3 (PTX3) concentration with angiographic and clinical outcomes in patients with acute ST-segment elevation myocardial infarction (STEMI) treated by primary angioplasty. BACKGROUND:Whether concentration of PTX3, a sensitive marker of inflammation, associates with angiographic and clinical outcomes in STEMI patients treated by primary angioplasty is unknown. METHODS:We prospectively enrolled 335 consecutive patients with acute STEMI undergoing primary angioplasty. Blood samples for plasma PTX3 measurement were drawn in all patients at the emergency department before primary angioplasty, and were measured by ELISA method. RESULTS:The median PTX3 concentrations were higher in patients with thrombus burden grade 4 and 5 versus grade <4 on initial coronary angiogram (0.29 ng/ml vs. 0.24 ng/ml, p = .02), thrombolysis in myocardial infarction (TIMI) grade <3 vs. TIMI grade-3 flow after primary angioplasty (0.31 ng/ml vs. 0.24 ng/ml, p < .001), incomplete versus complete ST-segment resolution within 12 hr after angioplasty (0.29 ng/ml vs. 0.22 ng/ml, p = .001) and in patients who did not survive versus those who survived at 30 days (0.44 ng/ml vs. 0.26 ng/ml, p = .001). A linear correlation was observed between PTX3 concentration and baseline leukocyte count (Spearman correlation = 0.21, p < .001). After adjustment for laboratory and selected clinical variables, patients in the highest quartile of PTX3 concentration (≥0.4 ng/ml) were associated with increased risk of 30-day mortality (hazard ratio = 11.83; 95% confidence interval = 1.52-92.27, p = .01). CONCLUSION:This study suggests that higher plasma PTX3 concentration associates with worse angiographic and clinical outcomes in STEMI patients treated by primary angioplasty.
PMID: 31782880
ISSN: 1522-726x
CID: 5222572
Outcomes in non-ST-segment elevation myocardial infarction patients according to heart failure at admission: Insights from a large trial with systematic early invasive strategy
Popovic, Batric; Sorbets, Emmanuel; Abtan, Jeremie; Cohen, Marc; Pollack, Charles V; Bode, Christoph; Wiviott, Stephen D; Sabatine, Marc S; Mehta, Shamir R; Ruzyllo, Witold; Rao, Sunil V; French, William J; Kerkar, Prafulla; Kiss, Robert G; Estrada, Jose Luis N; Elbez, Yedid; Ducrocq, Gregory; Steg, Philippe Gabriel
BACKGROUND:Previous studies published before the era of systematic early invasive strategy have reported a higher mortality in non-ST-segment elevation myocardial infarction patients with heart failure. The aim of our study was to compare the clinical characteristics, outcomes and causes of death of patients according to their heart failure status at admission in a large non-ST-segment elevation myocardial infarction population with planned early invasive management. METHODS:We performed a post-hoc analysis of the Treatment of Acute Coronary Syndrome with Otamixaban randomised trial which included non-ST-segment elevation myocardial infarction patients with systematic coronary angiography within 72 h. Patients were categorised according to presence or absence of heart failure (Killip grade ≥2) at admission. RESULTS: = 0.04). CONCLUSION/CONCLUSIONS:Non-ST-segment elevation myocardial infarction patients with heart failure at admission still have worse outcomes than those without heart failure, even with systematic early invasive strategy. Further efforts are needed to improve the prognosis of these high risk patients.
PMID: 33081496
ISSN: 2048-8734
CID: 5222862
Trends and Outcomes of Fibrinolytic Therapy for STEMI: Insights and Reflections in the COVID-19 Era [Letter]
Elbadawi, Ayman; Mahtta, Dhruv; Elgendy, Islam Y; Saad, Marwan; Krittanawong, Chayakrit; Hira, Ravi S; Omer, Mohamed; Ogunbayo, Gbolahan O; Garratt, Kirk; Rao, Sunil V; Jneid, Hani
PMCID:7535804
PMID: 33032721
ISSN: 1876-7605
CID: 5222832
SCAI Position Statement on the Performance of Percutaneous Coronary Intervention in Ambulatory Surgical Centers
Box, Lyndon C; Blankenship, James C; Henry, Timothy D; Messenger, John C; Cigarroa, Joaquin E; Moussa, Issam D; Snyder, Richard W; Duffy, Peter L; Carr, Jeffrey G; Tukaye, Deepali N; Ang, Lawrence; Shah, Binita; Rao, Sunil V; Mahmud, Ehtisham
The Centers for Medicare and Medicaid Services (CMS) began reimbursement for percutaneous coronary intervention (PCI) performed in ambulatory surgical centers (ASC) in January 2020. The ability to perform PCI in an ASC has been made possible due to the outcomes data from observational studies and randomized controlled trials supporting same day discharge (SDD) after PCI. In appropriately selected patients for outpatient PCI, clinical outcomes for SDD or routine overnight observation are comparable without any difference in short-term or long-term adverse events. Furthermore, a potential for lower cost of care without a compromise in clinical outcomes exists. These studies provide the framework and justification for performing PCI in an ASC. The Society for Cardiovascular Angiography and Interventions (SCAI) supported this coverage decision provided the quality and safety standards for PCI in an ASC were equivalent to the hospital setting. The current position paper is written to provide guidance for starting a PCI program in an ASC with an emphasis on maintaining quality standards. Regulatory requirements and appropriate standards for the facility, staff and physicians are delineated. The consensus document identified appropriate patients for consideration of PCI in an ASC. The key components of an ongoing quality assurance program are defined and the ethical issues relevant to PCI in an ASC are reviewed. This article is protected by copyright. All rights reserved.
PMID: 32406995
ISSN: 1522-726x
CID: 4438192
Trial Design Principles for Patients at High Bleeding Risk Undergoing PCI: JACC Scientific Expert Panel
Capodanno, Davide; Morice, Marie-Claude; Angiolillo, Dominick J; Bhatt, Deepak L; Byrne, Robert A; Colleran, Roisin; Cuisset, Thomas; Cutlip, Donald; Eerdmans, Pedro; Eikelboom, John; Farb, Andrew; Gibson, C Michael; Gregson, John; Haude, Michael; James, Stefan K; Kim, Hyo-Soo; Kimura, Takeshi; Konishi, Akihide; Leon, Martin B; Magee, P F Adrian; Mitsutake, Yoshiaki; Mylotte, Darren; Pocock, Stuart J; Rao, Sunil V; Spitzer, Ernest; Stockbridge, Norman; Valgimigli, Marco; Varenne, Olivier; Windhovel, Ute; Krucoff, Mitchel W; Urban, Philip; Mehran, Roxana
Investigating the balance of risk for thrombotic and bleeding events after percutaneous coronary intervention (PCI) is especially relevant for patients at high bleeding risk (HBR). The Academic Research Consortium for HBR recently proposed a consensus definition in an effort to standardize the patient population included in HBR trials. The aim of this consensus-based document, the second initiative from the Academic Research Consortium for HBR, is to propose recommendations to guide the design of clinical trials of devices and drugs in HBR patients undergoing PCI. The authors discuss the designs of trials in HBR patients undergoing PCI and various aspects of trial design specific to HBR patients, including target populations, intervention and control groups, primary and secondary outcomes, and timing of endpoint reporting.
PMID: 32943165
ISSN: 1558-3597
CID: 4593422
Multimodality Imaging in Evaluation of Cardiovascular Complications in Patients With COVID-19: JACC Scientific Expert Panel
Rudski, Lawrence; Januzzi, James L; Rigolin, Vera H; Bohula, Erin A; Blankstein, Ron; Patel, Amit R; Bucciarelli-Ducci, Chiara; Vorovich, Esther; Mukherjee, Monica; Rao, Sunil V; Beanlands, Rob; Villines, Todd C; Di Carli, Marcelo F
Standard evaluation and management of the patient with suspected or proven cardiovascular complications of coronavirus disease-2019 (COVID-19), the disease caused by severe acute respiratory syndrome related-coronavirus-2 (SARS-CoV-2), is challenging. Routine history, physical examination, laboratory testing, electrocardiography, and plain x-ray imaging may often suffice for such patients, but given overlap between COVID-19 and typical cardiovascular diagnoses such as heart failure and acute myocardial infarction, need frequently arises for advanced imaging techniques to assist in differential diagnosis and management. This document provides guidance in several common scenarios among patients with confirmed or suspected COVID-19 infection and possible cardiovascular involvement, including chest discomfort with electrocardiographic changes, acute hemodynamic instability, newly recognized left ventricular dysfunction, as well as imaging during the subacute/chronic phase of COVID-19. For each, the authors consider the role of biomarker testing to guide imaging decision-making, provide differential diagnostic considerations, and offer general suggestions regarding application of various advanced imaging techniques.
PMCID:7375789
PMID: 32710927
ISSN: 1558-3597
CID: 5222792
Management of Acute Myocardial Infarction During the COVID-19 Pandemic: A Position Statement From the Society for Cardiovascular Angiography and Interventions (SCAI), the American College of Cardiology (ACC), and the American College of Emergency Physicians (ACEP)
Mahmud, Ehtisham; Dauerman, Harold L; Welt, Frederick G P; Messenger, John C; Rao, Sunil V; Grines, Cindy; Mattu, Amal; Kirtane, Ajay J; Jauhar, Rajiv; Meraj, Perwaiz; Rokos, Ivan C; Rumsfeld, John S; Henry, Timothy D
The worldwide pandemic caused by the novel acute respiratory syndrome coronavirus 2 has resulted in a new and lethal disease termed coronavirus disease-2019 (COVID-19). Although there is an association between cardiovascular disease and COVID-19, the majority of patients who need cardiovascular care for the management of ischemic heart disease may not be infected with this novel coronavirus. The objective of this document is to provide recommendations for a systematic approach for the care of patients with an acute myocardial infarction (AMI) during the COVID-19 pandemic. There is a recognition of two major challenges in providing recommendations for AMI care in the COVID-19 era. Cardiovascular manifestations of COVID-19 are complex with patients presenting with AMI, myocarditis simulating an ST-elevation myocardial infarction (STEMI) presentation, stress cardiomyopathy, non-ischemic cardiomyopathy, coronary spasm, or nonspecific myocardial injury, and the prevalence of COVID-19 disease in the U.S. population remains unknown with risk of asymptomatic spread. This document addresses the care of these patients focusing on 1) the varied clinical presentations; 2) appropriate personal protection equipment (PPE) for health care workers; 3) role of the Emergency Department, Emergency Medical System and the Cardiac Catheterization Laboratory; and 4) Regional STEMI systems of care. During the COVID-19 pandemic, primary PCI remains the standard of care for STEMI patients at PCI capable hospitals when it can be provided in a timely fashion, with an expert team outfitted with PPE in a dedicated CCL room. A fibrinolysis-based strategy may be entertained at non-PCI capable referral hospitals or in specific situations where primary PCI cannot be executed or is not deemed the best option.
PMCID:7173829
PMID: 32330544
ISSN: 1558-3597
CID: 5222702
Navigation of a Dormant AV Fistula for PCI in a Patient With High-Risk NSTEMI [Case Report]
Friede, Kevin A; Wegermann, Zachary K; Rao, Sunil V
Arteriovenous (AV) fistulae for hemodialysis in patients with end-stage renal disease usually prevents ipsilateral transradial access (TRA) for coronary angiography. We present a case of coronary angiography and percutaneous coronary intervention via left TRA with navigation through a dormant AV fistula in a patient with limited vascular access. (Level of Difficulty: Intermediate.).
PMCID:8312011
PMID: 34317031
ISSN: 2666-0849
CID: 5223032
Splanchnic Nerve Block for Chronic Heart Failure
Fudim, Marat; Boortz-Marx, Richard L; Ganesh, Arun; DeVore, Adam D; Patel, Chetan B; Rogers, Joseph G; Coburn, Aubrie; Johnson, Inneke; Paul, Amanda; Coyne, Brian J; Rao, Sunil V; Gutierrez, J Antonio; Kiefer, Todd L; Kong, David F; Green, Cynthia L; Jones, W Schuyler; Felker, G Michael; Hernandez, Adrian F; Patel, Manesh R
OBJECTIVES:We hypothesized that splanchnic nerve blockade (SNB) would attenuate increased exercise-induced cardiac filling pressures in patients with chronic HF. BACKGROUND:Chronic heart failure (HF) is characterized by limited exercise capacity driven in part by an excessive elevation of cardiac filling pressures. METHODS:This is a prospective, open-label, single-arm interventional study in chronic HF patients. Eligible patients had a wedge pressure ≥15 mm Hg at rest or ≥25 mm Hg with exercise on baseline right heart catheterization. Patients underwent cardiopulmonary exercise testing with invasive hemodynamic assessment, followed by percutaneous SNB with ropivacaine. RESULTS:(9.1 ± 2.5 vs. 9.8 ± 2.7 ml/kg/min; p = 0.053). CONCLUSIONS:SNB reduced resting and exercise-induced pulmonary arterial and wedge pressure with favorable effects on cardiac output and exercise capacity. Continued efforts to investigate short- and long-term effects of SNB in chronic HF are warranted. Clinical Trials Registration (Abdominal Nerve Blockade in Chronic Heart Failure; NCT03453151).
PMID: 32535123
ISSN: 2213-1787
CID: 5222772
Response by Amin et al to Letters Regarding Article, "The Evolving Landscape of Impella Use in the United States Among Patients Undergoing Percutaneous Coronary Intervention With Mechanical Circulatory Support" [Comment]
Amin, Amit P; Rao, Sunil V; Bach, Richard G; Curtis, Jeptha P; Desai, Nihar; McNeely, Christian; Al-Badarin, Firas; House, John A; Kulkarni, Hemant; Masoudi, Frederick A; Spertus, John A
PMID: 32776840
ISSN: 1524-4539
CID: 5222822